Status:
TERMINATED
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
Lead Sponsor:
GlaxoSmithKline
Conditions:
Schizophrenia
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This study was designed to compare the \[123\]I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients. Investigation of the potential influence...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Right-handed
- Smoker
- Healthy volunteer or schizophrenic patients as diagnosed by DSM IV criteria.
- Treatment naive patients or with Risperidone treatment for 2 months that have not received any depot neuroleptic during the last year.
- Women of childbearing potential must agree to acceptable method of birth control.
- Exclusion criteria:
- Any clinically or laboratory significant abnormality.
- Subjects receiving a radiation dose from other activities of more than 10 mSv over any 3 year period.
- Heart pacemaker, metallic prosthesis or other metallic body implants.
- History or presence of CNS conditions.
- History of substance dependence.
- History of or suffers from claustrophobia.
- Positive test for HBV (hepatitis B virus), HCV (hepatitis C virus) or HIV.
- Pregnant or lactating women.
Exclusion
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2005
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00364429
Start Date
July 1 2005
End Date
July 1 2005
Last Update
January 11 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Barcelona, Spain